{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-318429","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.473701+00:00","generated_at":"2026-05-16T13:12:09.333360+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome Phase 3 RINGSIDE trial of varegacestat meets primary endpoint with 84% risk reduction","bullets":["Progression-free survival HR=0.16 (95% CI 0.071-0.375, p<0.0001) vs placebo in desmoid tumors.","Confirmed ORR 56% with varegacestat vs 9% with placebo (p<0.0001); median tumor volume change -83% vs +11%.","All key secondary endpoints met; safety consistent with GSI class (most common AEs: diarrhea 82%, fatigue 44%, rash 43%).","NDA submission to FDA planned for Q2 2026; additional data to be presented at upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-318429","json":"https://secwatch.observer/filing/0001193125-25-318429.json","markdown":"https://secwatch.observer/filing/0001193125-25-318429.md","text":"https://secwatch.observer/filing/0001193125-25-318429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/0001193125-25-318429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:12:09.333360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}